Back to top
more

Labcorp (LH)

(Delayed Data from NYSE)

$216.00 USD

216.00
308,627

+0.93 (0.43%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $216.01 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Riya Anand headshot

3 Diagnostics Stocks in Focus on Biden's Delta Variant Mandate

Stocks like Quest Diagnostics (DGX), Quidel Corporation (QDEL) and LabCorp (LH) are the right picks now, thanks to rising COVID-19 testing demand.

Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?

Strong performance by the Clinical Solutions and Commercial Solutions segments drove Syneos Health's (SYNH) top line.

Labcorp (LH) Base Business Grows Amid a Tough Volume Scenario

LabCorp (LH) plans to acquire the autoimmune business unit from Myriad Genetics, including Vectra, a rheumatoid arthritis assay.

Here's Why You Should Hold on to LabCorp (LH) Stock Now

Investors are optimistic about LabCorp (LH) on recovery in its base business and a raised 2021 guidance.

LabCorp (LH) Inks Deal to Assess Disparities in Drug Development

LabCorp (LH) and CCORN partner to develop a patient registry and biobank to help design cancer clinical trials in diverse populations.

Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving It?

A faster-than-expected recovery in base business and stabilized demand for COVID-19 testing instill optimism in Quest Diagnostics (DGX).

Urmimala Biswas headshot

4 Medical Device Stocks Set to Beat This Earnings Season

Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.

OPKO Health's (OPK) Q2 Earnings Lag Estimates, Margins Down

OPKO Health's (OPK) second-quarter results benefit from strength in both its reportable segments.

Merit Medical's (MMSI) Q2 Earnings Top Estimates, '21 View Up

Merit Medical (MMSI), in the second quarter, benefits from revenue growth across both its segments as well as across all the product categories within its Cardiovascular unit.

Integer Holdings (ITGR) Beats on Q2 Earnings, Ups 2021 View

Integer Holdings' (ITGR) second-quarter results reflect robust segmental performances along with strength in majority of the product lines.

QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline

Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.

Teleflex (TFX) Q2 Earnings Surpass Estimates, Margins Up

Teleflex (TFX) reports better-than-expected revenues with strong segmental and geographical performance driving the top line in second-quarter 2021.

Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up

Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.

Bio-Rad (BIO) Q2 Earnings Top Estimates, 2021 View Raised

Strength in Life Science and Clinical Diagnostics segments during the second quarter drove Bio-Rad (BIO) revenues.

IDEXX (IDXX) Q2 Earnings Beat Estimates, 2021 Guidance Up

Strength in CAG Diagnostics and Water businesses drove IDEXX's (IDXX) second-quarter revenues.

Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up

Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.

DexCom (DXCM) Q2 Earnings and Revenues Surpass Estimates

DexCom's (DXCM) second-quarter results benefit from domestic and international revenue growth and solid new customer additions.

NextGen Healthcare (NXGN) Q1 Earnings & Revenues Top Estimates

NextGen Healthcare's (NXGN) fiscal first-quarter earnings reflect strong segmental performance.

Cerner (CERN) Q2 Earnings and Revenues Surpass Estimates

Cerner's (CERN) second-quarter results benefit from gains across six of its business units.

LabCorp (LH) Q2 Earnings Surpass Estimates, 2021 View Raised

LabCorp (LH) Diagnostics revenues in the second quarter increase significantly on organic Base Business volume improvements despite decelerating demand for COVID-19 testing.

LabCorp (LH) Q2 Earnings and Revenues Beat Estimates

LabCorp (LH) delivered earnings and revenue surprises of 8.69% and 7.08%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) to Report Q2 Earnings: What's in the Cards? (revised)

LabCorp's (LH) second-quarter base-business performance is expected to have registered a faster recovery rate compared to the first quarter.

What's in Store for Henry Schein (HSIC) in Q2 Earnings?

Henry Schein's (HSIC) PPE sales from medical business are likely to have maintained momentum in Q2. Also, global recovery trends of its dental business are expected to reflect on Q2 results.

STERIS (STE) to Report Q1 Earnings: What's in the Cards?

Acquisitions of Cantel Medical and Key Surgical are expected to have contributed significantly to STERIS' (STE) first-quarter revenues.

What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?

IDEXX's (IDXX) fiscal second-quarter top line is expected to have benefited from strength in CAG and LPD businesses.